Following lung health in children and young adults with cancer
Monitors lung function over time in young people after a childhood cancer diagnosis.
Plain-language title generated from the registry record
Registry title: Early Pulmonary Dysfunction in Childhood Cancer Patients
Key facts
- Where
- Basel, Bern, Geneva, Lausanne, and Zurich, SwitzerlandSee the 5 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 22 years old?
Source: NCT05427136, who can take part
Where in Switzerland
- University Children's Hospital Basel (UKBB)Basel, SwitzerlandTaking people
- Universitätsklinik für KinderheilkundeBern, SwitzerlandTaking people
- Geneva University HospitalGeneva, SwitzerlandTaking people
- Centre Hospitalier Universitaire Vaudois LausanneLausanne, SwitzerlandTaking people
- Universitäts-Kinderspital ZürichZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Children's Hospital Basel
- Trial code
- NCT05427136
- Record updated
- 8 May 2026
- Original description
This longitudinal, prospective, multicentre study is to monitor lung function prospectively in childhood cancer patients after diagnosis. The impact of cancer treatment on pulmonary dysfunction non-invasively using lung function, lung imaging and breath analysis as well as clinical symptoms using a questionnaire will be assessed at different time points.Read full original descriptionShow less
Prospective Multicentre Cohort Study of Early Pulmonary Dysfunction in Childhood Cancer Patients (SWISS-Pearl Study)
This longitudinal, prospective, multicentre study is to monitor lung function prospectively in childhood cancer patients after diagnosis. The impact of cancer treatment on pulmonary dysfunction non-invasively using lung function, lung imaging and breath analysis as well as clinical symptoms using a questionnaire will be assessed at different time points.
Inclusion: at least one of the following cancer treatments:; chest radiation; treatment with any kind of chemotherapy; hematopoietic stem cell transplantation (HSCT); thoracic surgery; consent for Childhood Cancer Registry (ChCR) registration.
Exclusion: In addition for MRI and lung function tests:; Subjects who are respiratory insufficient and cannot perform a lung function test (less than 92% O2 saturation; under O2 therapy); Pregnant; MRI measurement not possible without sedation; Metal (e.g. pacemaker) in the body; Operation outside the chest area as only cancer treatment; Relapsed cancer (patients who develop relapse during the study will not be excluded); no signed informed consent.